Sep. 26 at 4:17 PM
$IBIO $IBIO for valuation purposes we can look at Lilly’s ~
$2B acquisition of Versanis Bio, mid 2023, for a mid stage activin A blocking asset. The other player in muscle preserving activin A biology is Regeneron with an in house developed asset. These drugs are pan activin while IBIO-610 is the first to target activin E which is both highly validated and more targeted and specific to fat loss than activin A and until now was considered too hard to target. The market for muscle sparing drugs in obesity is expected to be ~
$30B by 2035 according to Cowen. The space is hot and will get hotter 🤷♂️
